Aires Pharmaceuticals, Inc. is a privately-held clinical stage pharmaceutical company developing therapies to treat pulmonary vascular disorders. Founded in December 2006, the company has exclusive licenses to technology from the National Institutes of Health and the University of Cincinnati.
Aires Pharmaceuticals is developing a novel inhaled drug called Aironite® that has been demonstrated in animal models to treat both adult and pediatric pulmonary hypertension. Aironite has received Orphan Drug status by the U.S. FDA for treatment of pulmonary arterial hypertension (PAH). The company has completed two clinical trials and is proceeding with additional clinical studies.
|
CONSUMER ALERT!! Please be aware that over the past few weeks hundreds of people have received fraudulent letters that purport to be sent in conjunction with Aires Pharmaceuticals Inc. (“Aires”). These letters apparently contain bank checks that are designed to look like Aires bank checks. You should note that Aires did not send these letters or the purported checks, and the purported checks are fraudulent. Instead, Aires has been a victim of identity theft and is taking all necessary steps to address the situation. If you receive one of these letters and/or checks, please immediately contact the Federal Trade Commission at 1-877-382-4357 and your local police department to file a report. You should not attempt to deposit any purported check from Aires, as the check will be returned unpaid and you will most likely incur bank fees. Thank you. |